 | Intercept Pharmaceuticals, Inc. to Post FY2023 Earnings of ($8.31) Per Share, Oppenheimer Forecasts (NASDAQ:ICPT)
marketbeat.com - October 5 at 7:45 AM |
| Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Short Interest Down 9.7% in September
marketbeat.com - October 2 at 10:52 AM |
| Intercept Pharmaceuticals (NASDAQ:ICPT) PT Lowered to $49.00 at Piper Sandler
marketbeat.com - September 30 at 11:27 AM |
 | Intercept Pharmaceuticals (NASDAQ:ICPT) PT Lowered to $17.00
americanbankingnews.com - October 3 at 7:44 AM |
| Intercept Pharmaceuticals (NASDAQ:ICPT) Given New $49.00 Price Target at Piper Sandler
americanbankingnews.com - October 3 at 2:44 AM |
 | Institutional owners may take dramatic actions as Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) recent 8.5% drop adds to one-year losses
finance.yahoo.com - October 2 at 10:53 AM |
 | Intercept Pharma's liver disease drug fails late-stage trial
reuters.com - September 30 at 1:49 PM |
 | Intercept stock slumps 18% as liver disease drug fails phase 3 trial
seekingalpha.com - September 30 at 1:49 PM |
 | Intercept Pharmaceuticals Shares Slide After NASH Study Miss >ICPT
marketwatch.com - September 30 at 1:49 PM |
| Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients
finance.yahoo.com - September 30 at 1:49 PM |
| Intercept Phase 3 Compensated Cirrhosis NASH Study Misses Primary Endpoint >ICPT
marketwatch.com - September 30 at 8:49 AM |
|
| Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
finance.yahoo.com - September 30 at 8:49 AM |
| Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
finance.yahoo.com - September 26 at 2:17 PM |
 | B.Riley Financial Reaffirms Their Buy Rating on Intercept Pharma (ICPT)
markets.businessinsider.com - September 22 at 6:40 AM |
| Intercept Pharma Summarizes Key Actions in Strategic Financial Repositioning
finance.yahoo.com - September 21 at 3:37 PM |
| Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
finance.yahoo.com - September 21 at 10:37 AM |
| Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
finance.yahoo.com - September 20 at 7:33 PM |
| Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
finance.yahoo.com - September 7 at 9:46 AM |
| Why Is Intercept (ICPT) Up 15.4% Since Last Earnings Report?
finance.yahoo.com - September 2 at 3:31 PM |
| Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022
finance.yahoo.com - August 29 at 3:04 PM |
| Implied Volatility Surging for Intercept Pharmaceuticals (ICPT) Stock Options
finance.yahoo.com - August 29 at 3:04 PM |
 | Noteworthy Tuesday Option Activity: ICPT, IPI, ORCL
nasdaq.com - August 23 at 5:56 PM |
| Raymond James Maintains Outperform Rating for Intercept Pharmaceuticals: Here's What You Need To Know
markets.businessinsider.com - August 22 at 2:02 PM |
| What 6 Analyst Ratings Have To Say About Intercept Pharmaceuticals
markets.businessinsider.com - August 22 at 2:02 PM |
 | Check Out What Whales Are Doing With ICPT
benzinga.com - August 19 at 3:50 PM |
| Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva
finance.yahoo.com - August 18 at 1:31 PM |
| Intercept Pharmaceuticals to Participate in B. Riley’s PBC Symposium on August 24, 2022
finance.yahoo.com - August 18 at 8:31 AM |
| Intercept, Dr. Reddy’s settle patent dispute over Oclaiva generics
seekingalpha.com - August 17 at 5:29 PM |
 | Intercept Pharmaceuticals PT Lowered to $16 at H.C. Wainwright
investing.com - August 8 at 6:59 AM |
| Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)
finance.yahoo.com - August 5 at 8:25 AM |
| Where Intercept Pharmaceuticals Stands With Analysts
markets.businessinsider.com - August 4 at 4:07 PM |
|
| Intercept (ICPT) Earnings and Sales Miss Estimates in Q2
finance.yahoo.com - August 4 at 11:06 AM |
| Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 3:55 PM |
| Intercept Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - August 3 at 10:40 AM |
| Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 3 at 10:40 AM |
 | Intercept Pharmaceuticals Inc Stock News
morningstar.com - July 29 at 4:55 AM |
| Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
finance.yahoo.com - July 27 at 11:29 AM |
| Needham Cuts Price Target On This NASH-Focused Stock As Its Awaits Visibility On Regulatory Path
finance.yahoo.com - July 8 at 9:06 PM |
| The NASH Drug Dream Isn’t Dead Yet. Intercept is Asking FDA for Approval Again.
finance.yahoo.com - July 8 at 4:05 PM |
| Intercept (ICPT) Reports Positive Data From NASH Study on OCA
finance.yahoo.com - July 8 at 4:05 PM |
| Intercept to go back to FDA with its NASH treatment application
reuters.com - July 8 at 4:48 AM |
| Intercept Shares Fall After Interim Analysis On Late-Stage NASH Study
markets.businessinsider.com - July 7 at 6:43 PM |
| Intercept to resubmit NASH treatment application for FDA review
nasdaq.com - July 7 at 6:43 PM |
| Intercept to resubmit for FDA approval of NASH candidate after new analysis
seekingalpha.com - July 7 at 6:43 PM |
| UPDATE 2-Intercept to go back to FDA with its NASH treatment application
finance.yahoo.com - July 7 at 6:43 PM |
| Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt
finance.yahoo.com - July 7 at 6:43 PM |
| Intercept Reports More Positive Phase 3 Data From NASH Study >ICPT
marketwatch.com - July 7 at 8:03 AM |
| Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
finance.yahoo.com - July 7 at 8:03 AM |
| Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?
finance.yahoo.com - June 24 at 4:00 PM |
| Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022
finance.yahoo.com - June 21 at 11:14 AM |
| Intercept Announces PBC Data Presentations at The International Liver Congress™ 2022
finance.yahoo.com - June 21 at 11:14 AM |
| Intercept announces delay for key FDA meeting ahead of filing for NASH candidate
seekingalpha.com - June 6 at 8:25 AM |
| Intercept Provides Update on NASH Regulatory Timeline
finance.yahoo.com - June 6 at 8:25 AM |
